KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$6.1 million.

  • Emergent BioSolutions' Net Cash Flow fell 125.29% to -$21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 32.24%. This contributed to the annual value of -$6.1 million for FY2024, which is 98.85% up from last year.
  • As of FY2024, Emergent BioSolutions' Net Cash Flow stood at -$6.1 million, which was up 98.85% from -$529.7 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Net Cash Flow high stood at $454.5 million for FY2020, and its period low was -$529.7 million during FY2023.
  • Over the past 3 years, Emergent BioSolutions' median Net Cash Flow value was -$6.1 million (recorded in 2024), while the average stood at -$156.7 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Net Cash Flow surged by 723.37% in 2020, and later slumped by 905.02% in 2023.
  • Emergent BioSolutions' Net Cash Flow (Yearly) stood at $454.5 million in 2020, then plummeted by 109.88% to -$44.9 million in 2021, then spiked by 246.55% to $65.8 million in 2022, then slumped by 905.02% to -$529.7 million in 2023, then soared by 98.85% to -$6.1 million in 2024.